CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Astellas US LLC v. Hospira Inc.

1:12-cv-00652

Overview

Case Number 1:12-cv-00652
Filing Date 2012-05-23
Status Terminated
Termination Date 2012-09-27
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement

Parties

Plaintiff

Item Development AB NPE (Individual / Inventor)

Represented By

0 Attorneys Listed
No attorneys available

Astellas Pharma US, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Astellas US LLC Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Hospira Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 8 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 3 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (8): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (3 found):
U.S. Courts: 3
U.S. District Court 2012-12-12
1:12-cv-01699

Astellas US LLC v. Fresenius Kabi USA LLC

Asserted Patent
Status: DED
U.S. District Court 2012-11-19
1:12-cv-01489

Astellas US LLC v. Akorn Inc.

Asserted Patent
Status: DED
U.S. District Court 2005-05-26
1:05-cv-00337

King Pharmaceuticals Research and Development, Inc. v. SICOR Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5731296
Selective vasodilation by continuous adenosine infusion
Filed: 1993-03-15
Issued: 1998-03-24
Expired (Term Ended)
Expires: 2013-03-15

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(3 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Hospira Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 0311-1079353.) - filed by Astellas US LLC, Astellas Pharma US, Inc., Item Development AB. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(els) (Entered: 05/24/2012)

Entry #1 • 2012-05-23
PACER Document

SEALED STIPULATION to Stay by Astellas Pharma US, Inc., Astellas US LLC, Hospira Inc., Item Development AB. (Noreika, Maryellen) (Entered: 08/10/2012)

Entry #10 • 2012-08-10
PACER Document

PROPOSED CONSENT JUDGMENT -- JUDGMENT AND INJUNCTION ON CONSENT -- by Astellas Pharma US, Inc., Astellas US LLC, Hospira Inc., Item Development AB. (Noreika, Maryellen) (Entered: 09/26/2012)

Entry #13 • 2012-09-26
PACER Document

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc